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with radiotherapy at some point during their care. While older, 3D conformal radiation results in long-term xerostomia in up to 80% of patients, use of intensitymodulated radiotherapy (IMRT) can decrease the xerostomia rate to 20% to 30% (2). Patients left with radiationinduced xerostomia can develop compromised dentition, impaired swallowing ability, and difficulty speaking. For patients that develop xerostomia, the associated symptoms can have a major negative impact on the overall quality of life and hinder the recovery process.
Importantly, xerostomia potentially affects a much larger cohort of patients who have one of several chronic illnesses. Over one million patients per year in the United States suffer from Sjögren syndrome and other associated autoimmune disorders; many of these experience xerostomia symptoms. (1). There is also evidence that patients with poorly controlled diabetes frequently suffer from xerostomia. The incidence of diabetes has reached near epidemic proportions in the United States with over 25 million diagnosed cases, and more than 10% of diabetics may suffer from extreme hyposalivation (defined by a resting salivary flow rate < 0.01 ml/min).
Many more diabetic patients complain of dry mouth or difficulty swallowing, which are typical of milder xerostomia (3).
Finally, a plethora of commonly prescribed mediations can result in xerostomia. While the exact number of patients who suffer from medication-induced xerostomia is not known, the widespread use of medications that promote xerostomia suggests that a significant number of patients are affected by this condition.
Current treatment options
Treatment options for radiation-induced xerostomia focus on avoiding or ameliorating damage to the major salivary glands (Table 1) . IMRT uses multiple beams and modulates intensity to limit the dose of radiation to the parotid or submandibular glands. Surgical transposition of the submandibular glands has also been used to move a gland out of the radiation field during the course of radiotherapy and return the gland once radiation therapy is complete (4, 5). The pharmacologic agent amifostine is used to mitigate the effects of radiation and must be delivered daily via i.v. injection throughout the course of radiotherapy. Unfortunately, amifostine only provides modest benefits, but causes substantial side effects (6, 7).
Treatments for symptomatic xerostomia are generally supportive in nature. For example, patients are encouraged to increase water consumption by keeping a water bottle present at all times and to specially prepare food to aid swallowing (8). Several pharmacologic treatments are available to increase salivary production in patients with normal salivary acinar structure. Pilocarpine is a nonselective muscarinic receptor agonist that stimulates the secretion of saliva and sweat (9), and salivary substitutes are marketed by several companies, such as Biotene, which produces a sodium monofluorophosphatecontaining line of oral care products. While these products successfully relieve xerostomia symptoms in some patients, uncover the critical pathways involved in the activity of this salivary stem cell population, Xiao and colleagues made an exciting finding that has the potential to affect current xerostomia treatment. Gene-expression analysis revealed that a subpopulation of cells highly expressed glial cell line-derived neurotrophic factor (GDNF). Importantly, mice given GDNF exhibited enhanced function and integrity of irradiated salivary glands without any apparent effects on head and neck tumor growth. While stem cell-based therapies likely will require the implantation of isolated stem cells to repopulate the affected gland, the results of Xiao et al. suggest a pharmacologic approach for improving salivary gland function. Although the motivation for their study was to improve salivary gland function following radiation, the findings of Xiao and colleagues have potential implications for the millions of Americans who suffer daily from chronic xerostomia that did not develop as the result of head and neck radiotherapy.
Conclusions
While the results of Xiao and colleagues are exciting, this study represents only a first step along the way to improved treatments for xerostomia patients. It remains to be determined whether GDNF treatment can protect salivary function for a multiweek course of fractionated radiation and how many GDNF treatments are required for long-term improvements in salivary function. Furthermore, the optimal timing of GDNF treatment (before or after the development of xerostomia) in non-radiation-induced xerostomia remains uncertain. Importantly, patients undergoing radiation therapy may represent a small minority of patients suffering controlled clinical studies reveal mixed responses (10, 11) . The primary limitation of these approaches is that they fail to address the underlying cause of xerostomia in many patients, inadequate or malfunctioning salivary cells.
Restoring normal salivary function
Unsurprisingly, the development of therapies to help restore normal salivary function in patients suffering from xerostomia is of great clinical interest. Recently, Baum and colleagues reported the use of adenoviral-mediated delivery of genes encoding the water channel aquaporin-1 into the salivary gland, which provided objective improvement in salivary production in about half of the subjects (12) . This type of adenoviral approach has the potential to provide a more permanent treatment of this symptom; however, the expected duration of improvement following transgene delivery and other challenges associated with viral gene therapy remains unknown. Intriguingly, transplantation of salivary stem cells within bioengineered organs has also shown promise in rat and mouse models of xerostomia (13) (14) (15) . However, this powerful approach remains years away from clinical implementation due to limited sources of human stem cells. In this issue, Xiao and colleagues built on earlier work demonstrating that transplantation of salivary stem cells into irradiated glands can improve hyposalivation (16, 17 
